Elligo patient network tops 1m following research group acquisition

By Melissa Fassbender contact

- Last updated on GMT

(Image: Getty/JONGHO SHIN)
(Image: Getty/JONGHO SHIN)

Related tags: Elligo Health Research, Clinical research

Elligo Health Research has acquired Protenium Clinical Research, a TX-based research group, which will gain access to new technology, support, and career opportunities, says VP.

Robert Strzinek, PhD, DO, leads Protenium Clinical Research with more than 15 years of experience. Following the acquisition, Dr. Strzinek will conduct research at his practice in partnership with the integrated research organization Elligo, providing his patients with access to clinical research as a care option via the Elligo Research Ready network.

Mary Costello, vice president, network management and patient advocacy, Elligo Health Research, said joining Elligo benefits not only patients, but also the Protenium team, by providing them access to technology, tools, and support.

“It is our experience that many community physicians leave research not due to the research itself but to all the administrative, regulatory, and logistical challenges that accompany it,”​ Costello told Outsourcing-Pharma.

“Elligo and our communities of research seeks to help by providing the expertise and teams physicians need to support their staff and focus on patients and the successful conduct of clinical trials,”​ she added.

All employees will be kept on, Costello said, with new career opportunities to be available for all of the team members as part of a broader community.

Post acquisition, Elligo’s network now includes more than one million patients.

Related news

Show more

Related products

show more

Stability Testing As a Quality Control Measure

Stability Testing As a Quality Control Measure

Frontage Laboratories | 19-Jun-2019 | Technical / White Paper

Stability testing is, in essence, a quality control process and is there¬fore a vital component of every phase of clinical development for both large and...

Manufacturing Cyto and Non-Cyto Drugs in One Facility

Manufacturing Cyto and Non-Cyto Drugs in One Facility

Baxter BioPharma Solutions | 05-Nov-2018 | Technical / White Paper

Recent market reports suggest increasing product niches, which may lead to decreasing numbers of units per product, making dedicated facilities less practical....

Baxter’s Oncology Contract Manufacturing

Baxter’s Oncology Contract Manufacturing

Baxter BioPharma Solutions | 29-Aug-2018 | Product Brochure

Baxter BioPharma Solutions’ FOYA award-winning facility in Halle/Westfalen, Germany, offers state-of-the-art parenteral cGMP manufacturing at one location,...

Related suppliers

Follow us

Products

View more

Webinars